See more : TT Electronics plc (TTGPF) Income Statement Analysis – Financial Results
Complete financial analysis of CERo Therapeutics Holdings, Inc. (CERO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CERo Therapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Huadian Power International Corporation Limited (HPIFY) Income Statement Analysis – Financial Results
- Taiwan Biomaterial Co., Ltd. (6649.TWO) Income Statement Analysis – Financial Results
- Stellantis N.V. (STLAP.PA) Income Statement Analysis – Financial Results
- Xilio Therapeutics, Inc. (XLO) Income Statement Analysis – Financial Results
- AudioCodes Ltd. (AUDC.TA) Income Statement Analysis – Financial Results
CERo Therapeutics Holdings, Inc. (CERO)
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 9.85M | 9.14M |
| General & Administrative | 2.89K | 2.13M | 2.48M |
| Selling & Marketing | 2.89M | 715.76K | -2.23M |
| SG&A | 2.89M | 2.84M | 251.71K |
| Other Expenses | 40.05K | -64.05K | -80.32K |
| Operating Expenses | 2.93M | 2.91M | 332.03K |
| Cost & Expenses | 2.93M | 2.91M | 332.03K |
| Interest Income | 491.57K | 142.12K | 986.71K |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.93K | 1.07M | 735.47K |
| EBITDA | -2.44M | -68.58K | -332.03K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.93M | -2.91M | -332.03K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 491.57K | 2.84M | 99.08K |
| Income Before Tax | -2.44M | -68.58K | -332.42K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 94.82K | 599.16K | -16.87K |
| Net Income | -2.54K | -667.74K | -315.55K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.39 | -0.10 | -0.01 |
| EPS Diluted | -0.39 | -0.10 | -0.01 |
| Weighted Avg Shares Out | 6.53M | 6.77M | 22.98M |
| Weighted Avg Shares Out (Dil) | 6.53M | 6.77M | 22.98M |
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the...
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate...
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation...
CERo Therapeutics, Inc. Provides Corporate Update
Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T...
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to...
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index falling over 200 points on Wednesday.
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of...
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides shareholders with a corporate...
Source: https://incomestatements.info
Category: Stock Reports